期刊
ONCOLOGIST
卷 16, 期 4, 页码 388-403出版社
WILEY
DOI: 10.1634/theoncologist.2010-0386
关键词
-
类别
资金
- Janssen Pharmaceutical Companies of Johnson & Johnson in Europe, Middle East, and Africa (EMEA)
The arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved. These agents have been investigated intensively in different treatment settings, providing us with data to make evidence-based decisions regarding the optimal management of patients. This review is an update to a previous summary of European treatment practices that examines new data that have been published or presented at congresses up to the end of 2010 and assesses their impact on treatment practices. The Oncologist 2011;16:388-403
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据